George Wright
Manager, HEOR
Expertise:
George Wright is a Manager, HEOR at EVERSANA and for the past 6 years has worked on numerous medical device projects to provide clients with the tools they need to engage and inform their customers. George holds a Ph.D. in Medical Sciences specializing in Physiology and Pharmacology and an Honors BSc majoring in Biology and Pharmacology from McMaster University. George has over 14 years of research experience in a wide variety of topics including pharmacology, gastroenterology, and computational biology. Since joining EVERSANA, George has become experienced in many different medical devices across a variety of specialties and procedures. His experience includes projects involving: developing and adapting budget impact and cost-effectiveness models, systematic literature reviews, meta-analyses and network meta-analyses, value briefs, global value dossiers, and peer-reviewed journal publications.
Articles by George Wright
Budget Impact Analysis of Minimally Invasive Versus Open Transforaminal Lumbar Interbody Fusion for Lumbar Degenerative Disease in Europe
When traditional therapies fail to provide relief from pain caused by lumbar degenerative diseases, surgical approaches such as transforaminal lumbar interbody fusion (TLIF) may be used. TLIF can be performed using traditional open techniques (O-TLIF) or minimally invasive techniques (MI-TLIF). Although the clinical differences between O-TLIF and MI-TLIF have been evaluated extensively in meta-analyses, there remains a lack of established economic evidence. To address this gap, this analysis, conducted by DePuy Synthes and supported by EVERSANA’s Value & Evidence group (George Wright and Ankita Kambli), investigated the budget impact of MI-TLIF versus O-TLIF for single-level fusion from a European hospital perspective. The study’s findings demonstrated that the clinical benefits of […]
Single-Arm Data: Turning Limitations into Strengths with Numbers
Randomized controlled trials (RCTs) are at the top of the evidence pyramid because they are designed to be unbiased. Unfortunately, for many medical devices, these types of studies are lacking. This is either because they are not required for 510K or post-market approval (PMA), or there are challenges with implementing a randomized study design. Clinical studies without a control group, otherwise known as single-arm studies, have become “the norm” for many device categories. For example, in the oncology space, there are hundreds of uncontrolled studies evaluating thermal ablation technologies! Drug-eluting stents are another category with a wealth of non-comparative data informing the coronary disease treatment space. However, any one of […]